Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06577987 · ClinicalTrials.gov registry record · Phase 1
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
A Phase 1 study of Cancer and Lung Cancer, sponsored by Circle Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 220
- Enrollment target
- 10
- Study locations
NCT06577987: Recruiting Phase 1 study of Cancer and Lung Cancer, sponsored by Circle Pharma.
NCT06577987 is a Phase 1 study of Cancer and Lung Cancer that is actively recruiting participants, run by Circle Pharma. The registered enrollment target is 220 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (94% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06577987, a Phase 1 study of Cancer and Lung Cancer, is actively recruiting participants, sponsored by Circle Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 220 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG CID-078 Monotherapy
Study Locations (10)
Texas
- MD Anderson Cancer Center - Houston
- NEXT Oncology - San Antonio
Florida
- Florida Cancer Specialists - Sarasota
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- START Midwest - Grand Rapids
Nevada
- Comprehensive Cancer Centers of Nevada - Las Vegas
Ohio
- UH Seidman Cancer Center - Cleveland
Oregon
- Oregon Health and Science University - Portland
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2024-08-14 |
| Est. Completion | 2027-03-14 |
| Phase | Phase 1 |
What NCT06577987 shows while recruiting
NCT06577987 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (94% lower).
The record links to 10 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which CID-078 Monotherapy is the first listed.
NCT06577987 lists 10 locations in 9 states (Texas, Florida, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT06577987 about?
NCT06577987 is a clinical study titled "Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies". This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.
What is the current status of trial NCT06577987?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 220 participants. The study started on 2024-08-14. Estimated completion is 2027-03-14.
What conditions does trial NCT06577987 study?
This clinical trial studies the following conditions: Cancer, Lung Cancer, Advanced Solid Tumor, Triple Negative Breast Cancer, Breast Neoplasms.
What interventions are being tested in trial NCT06577987?
The interventions under investigation include: CID-078 Monotherapy (DRUG).
Who is sponsoring clinical trial NCT06577987?
This trial is sponsored by Circle Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06577987 being conducted?
This trial has 10 study locations across Florida, Massachusetts, Michigan, Nevada, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06577987's enrollment target sits among peer trials
220 221st of 615 higher than 395 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI